Literature DB >> 28480066

Selective internal radiation therapy with SIR-Spheres in hepatocellular carcinoma and cholangiocarcinoma.

Eric A Wang1, Scott R Broadwell1, Ross J Bellavia1, Jeff P Stein1.   

Abstract

Hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) often present at stages where patients have limited treatment options. Use of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) resin microspheres has progressed as data increasingly speak to its utility in patients with both intermediate and late stage disease in these cancers. In anticipation of the pending completion of several prospective randomized controlled multicenter studies exploring the use of Y-90 resin microspheres in primary liver cancers, this article outlines mechanisms involved in SIRT administration and reviews key efficacy and safety data that are currently available in the literature involving use of this therapy in both HCC and ICC.

Entities:  

Keywords:  Hepatocellular carcinoma (HCC); SIR-Spheres; intrahepatic cholangiocarcinoma (ICC); radioembolization; yttrium-90 resin microspheres

Year:  2017        PMID: 28480066      PMCID: PMC5401864          DOI: 10.21037/jgo.2016.11.08

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  40 in total

1.  Intrahepatic cholangiocarcinoma: expert consensus statement.

Authors:  Sharon M Weber; Dario Ribero; Eileen M O'Reilly; Norihiro Kokudo; Masaru Miyazaki; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

2.  Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials.

Authors:  J M Llovet; J Bustamante; A Castells; R Vilana; M del C Ayuso; M Sala; C Brú; J Rodés; J Bruix
Journal:  Hepatology       Date:  1999-01       Impact factor: 17.425

3.  Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation.

Authors:  Bruno Sangro; Livio Carpanese; Roberto Cianni; Rita Golfieri; Daniele Gasparini; Samer Ezziddin; Philipp M Paprottka; Francesco Fiore; Mark Van Buskirk; Jose Ignacio Bilbao; Giuseppe Maria Ettorre; Rita Salvatori; Emanuela Giampalma; Onelio Geatti; Kai Wilhelm; Ralf Thorsten Hoffmann; Francesco Izzo; Mercedes Iñarrairaegui; Carlo Ludovico Maini; Carlo Urigo; Alberta Cappelli; Alessandro Vit; Hojjat Ahmadzadehfar; Tobias Franz Jakobs; Secondo Lastoria
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

4.  Toxicities after radioembolization with yttrium-90 SIR-spheres: incidence and contributing risk factors at a single center.

Authors:  Peachy Mae Piana; Carin F Gonsalves; Takami Sato; P Rani Anne; Jeffrey W McCann; Voichita Bar Ad; David J Eschelman; Laurence Parker; Laura A Doyle; Daniel B Brown
Journal:  J Vasc Interv Radiol       Date:  2011-07-20       Impact factor: 3.464

5.  Yttrium-90 radioembolization of hepatocellular carcinoma and metastatic disease to the liver.

Authors:  Robert J Lewandowski; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2006-03       Impact factor: 1.513

6.  Modified response evaluation criteria in solid tumors and European Association for The Study of the Liver criteria using delayed-phase imaging at an early time point predict survival in patients with unresectable intrahepatic cholangiocarcinoma following yttrium-90 radioembolization.

Authors:  Juan C Camacho; Nima Kokabi; Minzhi Xing; Hasmukh J Prajapati; Bassel El-Rayes; Hyun S Kim
Journal:  J Vasc Interv Radiol       Date:  2014-02       Impact factor: 3.464

7.  Transcatheter arterial chemoembolization (TACE) in the treatment of unresectable liver cancer.

Authors:  R Yamada; K Kishi; M Sato; T Sonomura; N Nishida; K Tanaka; Y Shioyama; M Terada; M Kimura
Journal:  World J Surg       Date:  1995 Nov-Dec       Impact factor: 3.352

8.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

9.  Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.

Authors:  Valérie Vilgrain; Mohamed Abdel-Rehim; Annie Sibert; Maxime Ronot; Rachida Lebtahi; Laurent Castéra; Gilles Chatellier
Journal:  Trials       Date:  2014-12-03       Impact factor: 2.279

10.  Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study.

Authors:  W Y Lau; W T Leung; S Ho; N W Leung; M Chan; J Lin; C Metreweli; P Johnson; A K Li
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  3 in total

1.  Selective Internal Radiation Therapy for Hepatocellular Carcinoma Across the Barcelona Clinic Liver Cancer Stages.

Authors:  Carlos Moctezuma-Velazquez; Aldo J Montano-Loza; Judith Meza-Junco; Kelly Burak; Mang Ma; Vincent G Bain; Norman Kneteman; Phillipe Sarlieve; Richard J Owen
Journal:  Dig Dis Sci       Date:  2020-04-12       Impact factor: 3.199

2.  Emerging trends in modeling human liver disease in vitro.

Authors:  Gregory H Underhill; Salman R Khetani
Journal:  APL Bioeng       Date:  2019-12-24

3.  Prognostic Factors for Overall Survival in Advanced Intrahepatic Cholangiocarcinoma Treated with Yttrium-90 Radioembolization.

Authors:  Michael Köhler; Fabian Harders; Fabian Lohöfer; Philipp M Paprottka; Benedikt M Schaarschmidt; Jens Theysohn; Ken Herrmann; Walter Heindel; Hartmut H Schmidt; Andreas Pascher; Lars Stegger; Kambiz Rahbar; Moritz Wildgruber
Journal:  J Clin Med       Date:  2019-12-25       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.